期刊
AMERICAN JOURNAL OF PSYCHIATRY
卷 178, 期 8, 页码 715-729出版社
AMER PSYCHIATRIC PUBLISHING, INC
DOI: 10.1176/appi.ajp.2020.20030250
关键词
-
类别
资金
- APA Foundation Research Fellowship
- Cervel Neurotherapeutics
- National Institute on Aging
- National Institute of Neurological Disease and Stroke
- NeoSync
- Neuronetics
- Patient-Centered Outcomes Research Institute
- Soterix
- Stanley Foundation
- Oxford University
- NIH
- Stanley Medical Research Institute
- Otsuka
- Biohaven Pharmaceuticals
- NIH [UH3NS100548, R21MH120785]
- NIMH
Mr. A, a 24-year-old man, presented with worsening depression. Despite a history of depression since adolescence and a troubled childhood, the clinical decision support system recommended a medication that led to complete remission of his symptoms.
Mr. A, a 24-year-old man, presents for evaluation of worsening depression. He describes a history of depression since adolescence, although he notes that he suffered a troubled childhood, including emotional neglect. He believes a recent breakup and having been denied a promotion precipitated this episode. I'm sleeping all the time, and my body feels heavy, he adds. He also reports increased appetite, weight gain, and urges to cut, which I have not done in years. However, he remains social and actively involved in several hobbies. He discontinued bupropion and escitalopram in the past because of terrible headaches and irritability. Initially, you consider starting lamotrigine. However, your office recently implemented a clinical decision support system that recommends a trial of phenelzine. The patient's symptoms remit entirely on the medication suggested by the system. Curious as to how the system decided on this treatment, you download several papers on its development.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据